(18)F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

por Mesci, Aruz, Ahmadi, Elham, Ali, Amr, Gouran-Savadkoohi, Mohammad, Evelyn Tsakiridis, Evangelia, Biziotis, Olga-Demetra, Chow, Tom, Kapoor, Anil, Sur, Monalisa, Steinberg, Gregory R., Liu, Stanley, Zukotynski, Katherine, Tsakiridis, Theodoros
Publicado 2023

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

por Tsakiridis, Evangelia E., Broadfield, Lindsay, Marcinko, Katarina, Biziotis, Olga-Demetra, Ali, Amr, Mekhaeil, Bassem, Ahmadi, Elham, Singh, Kanwaldeep, Mesci, Aruz, Zacharidis, Panayiotis G., Anagnostopoulos, Alexander E., Berg, Tobias, Muti, Paola, Steinberg, Gregory R., Tsakiridis, Theodoros
Publicado 2021

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

por Ali, Amr, Mekhaeil, Bassem, Biziotis, Olga-Demetra, Tsakiridis, Evangelia E., Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Mesci, Aruz, Liu, Stanley, Berg, Tobias, Bramson, Jonathan L., Steinberg, Gregory R., Tsakiridis, Theodoros
Publicado 2023

Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α

por Biziotis, Olga‐Demetra, Tsakiridis, Evangelia Evelyn, Ali, Amr, Ahmadi, Elham, Wu, Jianhan, Wang, Simon, Mekhaeil, Bassem, Singh, Kanwaldeep, Menjolian, Gabe, Farrell, Thomas, Abdulkarim, Bassam, Sur, Ranjan K., Mesci, Aruz, Ellis, Peter, Berg, Tobias, Bramson, Jonathan L, Muti, Paola, Steinberg, Gregory R, Tsakiridis, Theodoros
Publicado 2023